Ortin Laboratories (BOM:539287) 3-Year EBITDA Growth Rate : -56.40% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Ortin Laboratories 3-Year EBITDA Growth Rate?

Ortin Laboratories's EBITDA per Share for the three months ended in Dec. 2023 was ₹-3.20.

During the past 12 months, Ortin Laboratories's average EBITDA Per Share Growth Rate was -856.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -56.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -44.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -22.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ortin Laboratories was 19.20% per year. The lowest was -56.40% per year. And the median was -3.80% per year.

Competitive Comparison of Ortin Laboratories's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ortin Laboratories's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ortin Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Ortin Laboratories's 3-Year EBITDA Growth Rate falls into.

Ortin Laboratories 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Ortin Laboratories (BOM:539287) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Ortin Laboratories 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Ortin Laboratories's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ortin Laboratories (BOM:539287) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ortin Laboratories Ltd (BOM:539287) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

ORTINLAB:India

Address

Street no. 3, D. No. 1-8-B4, Ground Floor,Block-4, F3 HIG, Baghlingampally, Hyderabad, TG, IND, 500 044

Website

https://www.ortinlabsindia.com

Ortin Laboratories Ltd is an India based engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its APIs Intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zudavudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others.It earns key revenue from domestic sales.

Ortin Laboratories (BOM:539287) Headlines

No Headlines